Return to List

Study Summary
No. ID99-417:.......Unspecified......Christopher Logothetis......Genitourinary Medical Oncology
.
Study Summary Title
Study Summary
Number:		ID99-417
Study Title:Screening Phage Display Random Peptide Libraries in Humans
.
Physician New Patient Referral
Name:Christopher LogothetisPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Genitourinary Medical OncologyReferring MD
Call:		800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-792-2830
Contact us about clinical trials
.
General Information
Disease Group:UnspecifiedSupported By:N/A
Phase of Study:N/AReturn
Visit:		None
Treatment
Agents:		Phage Display Random Peptide LibrariesHome Care:None
Treatment Loc:Only at MDACC
Estimated
Length of Stay
in Houston:		Length of stay will not be influenced by study.
Description/
Intervention:		Unavailable
.
Study Objectives / Outcomes
1. To infuse phage display random peptide libraries in terminal wean patients or in brain dead human subjects

2. To screen for peptides that selectively home to tissue-specific vascular addresses.

3. To assess the surrogates' satisfaction with this mode of research and develop consensus guidelines for conducting research on this subject population.
.
Study Status Information
Study Activation / Registration Date:05/03/2000
IRB Review and Approval Date:01/19/2000
Study Type:Screening
Recruitment Status:Open
Projected Accrual:N/A
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
Inclusion Criteria:1) Patients for whom a terminal wean is planned or brain dead subjects.

2) Approval by the attending physician and intensive care unit physician.

3) Formal brain dead documentation (in case of subjects).

4) Legal surrogate agrees and signs written informed consent.

5) Ethics Component: Inclusion for Interview - a) Experimental group: the surrogate who gives the consent for participation of patients/subjects in the Phage Component; b) Control group: an equal number of surrogates of patients who were terminally weaned but who did not participate in the Phage Component.
Exclusion Criteria:1) Absence of responsible surrogate

2) HIV positive patients

3) Chronic hepatitis B or C infections

4) Active tuberculosis infections

5) Potential transplant organ donors

6) DIC or bleeding disorders
.
Links
Registration Number: Not Applicable Clinical Trial
Other Links:
.
Results

Return to Clinical Trials at M.D. Anderson Cancer Center